Unlock stock picks and a broker-level newsfeed that powers Wall Street.

ESSA Pharma And 2 Other US Penny Stocks To Watch

In This Article:

As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a relic of past trading days, still hold significant potential for growth and value discovery in today's market landscape. These smaller or newer companies can offer a mix of affordability and upside potential when backed by strong financials, presenting an underappreciated avenue for investors seeking hidden gems in the stock market.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.7656

$5.56M

★★★★★★

RLX Technology (NYSE:RLX)

$1.63

$2.07B

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$170.72M

★★★★★★

AsiaFIN Holdings (OTCPK:ASFH)

$0.97

$79.11M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$4.10

$51.05M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.44

$128.99M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$88.26M

★★★★☆☆

Permianville Royalty Trust (NYSE:PVL)

$1.55

$51.15M

★★★★★★

Puma Biotechnology (NasdaqGS:PBYI)

$2.88

$141.25M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$1.07

$96.23M

★★★★★☆

Click here to see the full list of 740 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

ESSA Pharma

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ESSA Pharma Inc. is a clinical-stage pharmaceutical company dedicated to developing small molecule drugs for prostate cancer treatment, with a market cap of $79.86 million.

Operations: ESSA Pharma Inc. has not reported any revenue segments as it is currently focused on the clinical development of small molecule drugs for prostate cancer treatment.

Market Cap: $79.86M

ESSA Pharma Inc., a pre-revenue company with a market cap of US$79.86 million, recently terminated its Phase 2 clinical trial for masofaniten due to lack of efficacy compared to standard treatment. Despite this setback, the company maintains a strong cash position with short-term assets of US$132.1 million far exceeding liabilities and no debt on its books, providing it with over three years of cash runway at current burn rates. While the stock is highly volatile and unprofitable, analysts forecast significant earnings growth ahead, supported by seasoned management and board experience.

NasdaqCM:EPIX Debt to Equity History and Analysis as at Nov 2024
NasdaqCM:EPIX Debt to Equity History and Analysis as at Nov 2024

Identiv

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Identiv, Inc. is a security technology company offering secure identification and physical security solutions globally, with a market cap of $92.73 million.